Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cord Blood Stem Cell Transplantation | 6 | 2021 | 372 | 0.650 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 18 | 2023 | 6982 | 0.630 |
Why?
|
| Fetal Blood | 5 | 2014 | 503 | 0.620 |
Why?
|
| Hematologic Neoplasms | 9 | 2023 | 1955 | 0.470 |
Why?
|
| Transplantation, Homologous | 11 | 2017 | 3033 | 0.360 |
Why?
|
| Stem Cell Transplantation | 2 | 2023 | 1424 | 0.300 |
Why?
|
| Graft vs Host Disease | 11 | 2022 | 2804 | 0.300 |
Why?
|
| Whole-Body Irradiation | 2 | 2021 | 324 | 0.290 |
Why?
|
| Osteopetrosis | 1 | 2006 | 26 | 0.270 |
Why?
|
| Leukemia | 2 | 2022 | 1720 | 0.250 |
Why?
|
| Melphalan | 3 | 2012 | 877 | 0.240 |
Why?
|
| Vidarabine | 3 | 2021 | 1383 | 0.240 |
Why?
|
| Radiography, Bitewing | 1 | 2003 | 1 | 0.230 |
Why?
|
| Lighting | 1 | 2003 | 25 | 0.220 |
Why?
|
| Dental Caries | 1 | 2003 | 24 | 0.220 |
Why?
|
| Interferon-alpha | 1 | 2006 | 960 | 0.200 |
Why?
|
| Dyskeratosis Congenita | 1 | 2021 | 26 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1734 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 7 | 2005 | 1773 | 0.180 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 99 | 0.180 |
Why?
|
| Cyclophosphamide | 7 | 2022 | 3231 | 0.180 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2020 | 135 | 0.170 |
Why?
|
| Unrelated Donors | 2 | 2022 | 321 | 0.160 |
Why?
|
| Neoplasms, Experimental | 2 | 1999 | 791 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 1838 | 0.150 |
Why?
|
| Child | 23 | 2023 | 30418 | 0.150 |
Why?
|
| Ganciclovir | 1 | 1998 | 194 | 0.150 |
Why?
|
| beta-Thalassemia | 3 | 2005 | 33 | 0.150 |
Why?
|
| Thymidine Kinase | 1 | 1998 | 224 | 0.150 |
Why?
|
| Acute Lung Injury | 1 | 2019 | 93 | 0.150 |
Why?
|
| Simplexvirus | 1 | 1998 | 181 | 0.150 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 1486 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2023 | 1068 | 0.150 |
Why?
|
| Adolescent | 21 | 2023 | 32577 | 0.140 |
Why?
|
| Immunotherapy | 2 | 2021 | 3532 | 0.140 |
Why?
|
| Necrosis | 1 | 1998 | 603 | 0.140 |
Why?
|
| Hematopoiesis | 3 | 2009 | 606 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 2899 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 631 | 0.130 |
Why?
|
| Transplantation Conditioning | 6 | 2017 | 2359 | 0.130 |
Why?
|
| Myeloproliferative Disorders | 1 | 2023 | 881 | 0.130 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 9043 | 0.120 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 1445 | 0.120 |
Why?
|
| Blood Preservation | 1 | 2014 | 60 | 0.110 |
Why?
|
| Busulfan | 4 | 2017 | 786 | 0.110 |
Why?
|
| Young Adult | 10 | 2023 | 22059 | 0.110 |
Why?
|
| Mouth Mucosa | 2 | 2006 | 225 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2022 | 7240 | 0.110 |
Why?
|
| Transplantation, Autologous | 4 | 2023 | 2049 | 0.100 |
Why?
|
| Humans | 39 | 2023 | 270946 | 0.100 |
Why?
|
| Neutropenia | 3 | 1999 | 1001 | 0.090 |
Why?
|
| Recurrence | 3 | 2022 | 4881 | 0.090 |
Why?
|
| Female | 27 | 2023 | 148508 | 0.080 |
Why?
|
| Cystitis | 1 | 2010 | 109 | 0.080 |
Why?
|
| BK Virus | 1 | 2010 | 126 | 0.080 |
Why?
|
| Polyomavirus Infections | 1 | 2010 | 149 | 0.080 |
Why?
|
| Copper | 1 | 2009 | 166 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 249 | 0.080 |
Why?
|
| Graft Survival | 3 | 2012 | 1091 | 0.080 |
Why?
|
| Neoplasms | 5 | 2022 | 15849 | 0.080 |
Why?
|
| Child, Preschool | 13 | 2021 | 16978 | 0.070 |
Why?
|
| Stomatitis | 2 | 2006 | 193 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2017 | 3145 | 0.070 |
Why?
|
| Tissue Donors | 3 | 2010 | 812 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 4840 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 1135 | 0.070 |
Why?
|
| Tacrolimus | 2 | 2016 | 351 | 0.070 |
Why?
|
| Fever | 2 | 1999 | 515 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2007 | 238 | 0.070 |
Why?
|
| Immune System | 1 | 2007 | 276 | 0.060 |
Why?
|
| Puberty, Delayed | 1 | 2005 | 7 | 0.060 |
Why?
|
| Regeneration | 1 | 2007 | 282 | 0.060 |
Why?
|
| Diarrhea | 2 | 2006 | 731 | 0.060 |
Why?
|
| Adult | 10 | 2023 | 81555 | 0.060 |
Why?
|
| Anti-Infective Agents | 2 | 1998 | 465 | 0.060 |
Why?
|
| Male | 20 | 2023 | 128453 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2004 | 609 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 1372 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 16593 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2004 | 356 | 0.050 |
Why?
|
| Sepsis | 1 | 2007 | 689 | 0.050 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2021 | 48 | 0.050 |
Why?
|
| Radiography | 1 | 2006 | 1990 | 0.050 |
Why?
|
| Ciprofloxacin | 2 | 1999 | 90 | 0.050 |
Why?
|
| Infant | 8 | 2006 | 13913 | 0.050 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 9 | 0.050 |
Why?
|
| Granulocytes | 1 | 2022 | 243 | 0.050 |
Why?
|
| Alemtuzumab | 1 | 2021 | 208 | 0.050 |
Why?
|
| Hypogonadism | 1 | 2005 | 309 | 0.050 |
Why?
|
| Observer Variation | 1 | 2003 | 723 | 0.050 |
Why?
|
| Thalassemia | 1 | 2000 | 28 | 0.050 |
Why?
|
| Mouth Diseases | 1 | 2001 | 37 | 0.050 |
Why?
|
| Histocompatibility Testing | 3 | 2016 | 483 | 0.050 |
Why?
|
| Siblings | 1 | 2022 | 299 | 0.050 |
Why?
|
| Thiotepa | 3 | 2012 | 132 | 0.050 |
Why?
|
| Endocrine System Diseases | 1 | 2000 | 91 | 0.040 |
Why?
|
| Survival Rate | 3 | 2012 | 12516 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 584 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2020 | 13351 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 381 | 0.040 |
Why?
|
| Graft vs Tumor Effect | 1 | 1999 | 143 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1998 | 85 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1999 | 98 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 824 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2020 | 839 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2016 | 2346 | 0.040 |
Why?
|
| Joint Diseases | 1 | 1998 | 71 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2022 | 39694 | 0.040 |
Why?
|
| Dapsone | 1 | 1997 | 15 | 0.040 |
Why?
|
| Health Resources | 1 | 1999 | 173 | 0.040 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1997 | 75 | 0.040 |
Why?
|
| Hospital Costs | 1 | 1999 | 252 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2003 | 1330 | 0.040 |
Why?
|
| Remission Induction | 2 | 2020 | 3645 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2021 | 670 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2023 | 1108 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2022 | 1424 | 0.030 |
Why?
|
| Nucleoside Deaminases | 1 | 1996 | 45 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 16186 | 0.030 |
Why?
|
| Ricin | 1 | 1995 | 39 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 1069 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 1467 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 1996 | 141 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 156 | 0.030 |
Why?
|
| Treatment Outcome | 7 | 2023 | 33827 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 4331 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 1999 | 507 | 0.030 |
Why?
|
| Immunotoxins | 1 | 1995 | 120 | 0.030 |
Why?
|
| Time Factors | 3 | 2017 | 13112 | 0.030 |
Why?
|
| Incidence | 2 | 2020 | 5843 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1999 | 604 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 3928 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1996 | 371 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 1998 | 5834 | 0.030 |
Why?
|
| Aged | 4 | 2023 | 73160 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1998 | 1021 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2020 | 1858 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 1999 | 750 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1996 | 812 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 684 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1335 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1996 | 1076 | 0.020 |
Why?
|
| Age Factors | 1 | 2021 | 5496 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 2004 | 596 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2012 | 237 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 2368 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1998 | 1732 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 4399 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 2000 | 435 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2426 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 14679 | 0.020 |
Why?
|
| Leukopenia | 1 | 2007 | 153 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1998 | 7813 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2007 | 310 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2007 | 485 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 733 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2000 | 1620 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2010 | 742 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2007 | 380 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2005 | 186 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 259 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 5108 | 0.010 |
Why?
|
| Mice | 3 | 1999 | 35992 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2007 | 1269 | 0.010 |
Why?
|
| Lichen Planus, Oral | 1 | 2001 | 9 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 15253 | 0.010 |
Why?
|
| Greece | 1 | 2000 | 28 | 0.010 |
Why?
|
| Lip | 1 | 2001 | 36 | 0.010 |
Why?
|
| Mucocele | 1 | 2001 | 23 | 0.010 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2000 | 23 | 0.010 |
Why?
|
| Episode of Care | 1 | 1999 | 9 | 0.010 |
Why?
|
| Testosterone | 1 | 2005 | 733 | 0.010 |
Why?
|
| Xerostomia | 1 | 2001 | 205 | 0.010 |
Why?
|
| Animals | 3 | 1999 | 62771 | 0.010 |
Why?
|
| Ceftazidime | 1 | 1999 | 66 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 5085 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2000 | 725 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1999 | 400 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 10349 | 0.010 |
Why?
|
| Cephalosporins | 1 | 1999 | 174 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 22458 | 0.010 |
Why?
|
| Premedication | 1 | 1997 | 133 | 0.010 |
Why?
|
| Digestive System Diseases | 1 | 1997 | 39 | 0.010 |
Why?
|
| Arthritis | 1 | 1998 | 149 | 0.010 |
Why?
|
| Immunization | 1 | 1999 | 403 | 0.010 |
Why?
|
| Dimethylhydrazines | 1 | 1996 | 3 | 0.010 |
Why?
|
| Cytosine Deaminase | 1 | 1996 | 43 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1999 | 7216 | 0.010 |
Why?
|
| Methylcholanthrene | 1 | 1996 | 33 | 0.010 |
Why?
|
| Middle Aged | 2 | 2016 | 90020 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1997 | 271 | 0.010 |
Why?
|
| Methotrexate | 1 | 1999 | 1027 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2001 | 1851 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1995 | 130 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1997 | 534 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 6027 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1995 | 322 | 0.010 |
Why?
|
| Carcinogens | 1 | 1996 | 391 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1997 | 770 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 1999 | 908 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 1997 | 426 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1996 | 11761 | 0.010 |
Why?
|
| Biopsy | 1 | 2001 | 3545 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 1345 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1995 | 575 | 0.010 |
Why?
|
| Antibodies | 1 | 1995 | 835 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1997 | 701 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1997 | 3542 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1996 | 721 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 17823 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1997 | 949 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1996 | 1884 | 0.010 |
Why?
|
| United States | 1 | 2007 | 15982 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 1997 | 2117 | 0.010 |
Why?
|
| Texas | 1 | 1999 | 6415 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1996 | 1437 | 0.000 |
Why?
|
| Risk Assessment | 1 | 1999 | 6837 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1997 | 9307 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 3177 | 0.000 |
Why?
|
| Bone Neoplasms | 1 | 1997 | 2669 | 0.000 |
Why?
|
| Disease Progression | 1 | 1996 | 6893 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 7936 | 0.000 |
Why?
|